MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)

Completed · Phase 1

Conditions studied: Diffuse Large B-Cell Lymphoma

In brief

The purpose of this study is to evaluate the safety, tolerability, and efficacy of MEDI4736 (durvalumab) alone and in combination with either tremelimumab or AZD9150 in adult subjects with relapsed or refractory dIffuse large B-cell lymphoma.

Key facts

Study ID

NCT02549651

Run by

MedImmune LLC

People needed

32

Starts

2016-07-13

Expected to finish

2019-02-04

Last updated by the study team

2019-02-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18 years
• Subjects with histologically confirmed relapsed or refractory DLBCL who have received at least 1 prior rituximab containing chemotherapy regimen but no more than 5 prior lines of therapy
• Eastern Cooperative Group (ECOG) performance status of 0 or 1
• Measurable disease by International Working Group (IWG) response criteria for lymphoma
• Adequate organ and marrow function

You may not qualify if…

• Previous immune-mediated therapy
• Subjects with prior ASCT or allogenic HCT. Subjects ineligible for available curative options after failing ASCT and have met the hematologic criteria are eligible to participate in this study. Subjects with prior allogenic HCT will be excluded.
• Documented current central nervous system involvement
• Active or prior documented autoimmune or inflammatory disease within 3 years, with some exceptions 4. Concurrent or prior conventional or investigational anticancer therapy, within 28 days prior to the first dose of study medication(s)

Where it is running

• Research Site — La Jolla, California, United States
• Research Site — Baltimore, Maryland, United States
• Research Site — Albuquerque, New Mexico, United States
• Research Site — Durham, North Carolina, United States
• Research Site — Charleston, South Carolina, United States
• Research Site — Dallas, Texas, United States
• Research Site — Houston, Texas, United States
• Research Site — Milwaukee, Wisconsin, United States
• Research Site — Marseille, France
• Research Site — Villejuif, France
• Research Site — Dublin, Ireland
• Research Site — Galway, Ireland
• Research Site — Leicester, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.